Leerink Partners analyst Mani Foroohar maintained a Hold rating on RegenXBio (NASDAQ:RGNX) on Wednesday, setting a price target of $43, which is approximately 17.52% above the present share price of $36.59.
Foroohar expects RegenXBio to post earnings per share (EPS) of -$1.36 for the fourth quarter of 2021.
The current consensus among 7 TipRanks analysts is for a Moderate Buy rating of shares in RegenXBio, with an average price target of $62.17.
The analysts price targets range from a high of $90 to a low of $43.
In its latest earnings report, released on 06/30/2021, the company reported a quarterly revenue of $22.04 million and a net profit of -$52.23 million. The company's market cap is $1.56 billion.
According to TipRanks.com, Leerink Partners analyst Mani Foroohar is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -16.8% and a 34.58% success rate.
REGENXBIO, Inc. is a biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. The company was founded by Kennth T. Mills and James M. Wilson on July 16, 2008 and is headquartered in Rockville, MD.